Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1078 participants.
Also called NCT00826059
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,078 participants
- Sponsor
- BrainsGate
- Registry
-
NCT00826059
-
- Other papers using this trial's data
- An injectable implant to stimulate the sphenopalatine ganglion for treatment of acute ischaemic stroke up to 24 h from onset (ImpACT-24B): an international, randomised, double-blind, sham-controlled, pivotal trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hong Kong SAR China, Israel, Italy, North Macedonia, Poland, Portugal, Serbia, Slovakia, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT00826059. Randomized; triple masking; primary purpose treatment. Start 2011-06 (actual); primary completion 2018-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window
- Acronym
- ImpACT-24B
- Condition
- Ischemic Stroke
- Intervention (Device)
- Active Sphenopalatine Ganglion (SPG) Stimulation
- Intervention (Device)
- Sham Sphenopalatine Ganglion (SPG) Stimulation
- Lead sponsor
- BrainsGate
Record details
- Record id
cardio:ct-nct00826059- Content hash
b06448055d1bb9d04be7d119995694304624a9962f46cdc45e09bc946693fe0a